Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
It is approved for: Adults with obesity (BMI 30) Adults who are overweight (BMI 27) with related conditions Children ages 12 and older with obesity Wegovy is used alongside a reduced-calorie diet and increased physical activity
Guidance on specific medications is below: Semaglutide: Useful unrefrigerated for 3 days, up to 90 degrees F
The investigation specifically showed that these drugs did not increase the risk of any fractures, confirming their safety profile in clinical practice (72)
You do not need to take your first Ozempic shot on an empty stomach
